Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS: SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.

Abstract

DALFAMPRIDINE; TREATMENT OF WALKING IMPAIRMENT IN MULTIPLE SCLEROSIS

Shraddha Autade*, R. B. Laware and G. S. Shinde

ABSTRACT

In Central Nervous System the multiple sclerosis is a potentially diabling disorder, in youngster this is incurable disorder.in this Physiopathology include: neurodegenerative and inflammatory demyelination. The inflaming demyelination of MS that is especially promoted by a massive activating of the immune system against putative CNS antigen(s) ends up in loss of myelin/oligodendrocyte complex that slows down or halts impulse conduction in denuded axons. The cause and curative for Multiple sclerosis remain undiscovered. A disease in which the immune system eats away at the protective covering of nerves. Dalfampridine is approved by FDA for treatment of MS. It is a potassium channel blocker which acts at the central and peripheral nervous systems, which increases conduction of in demyelinated axons and enhance walking ability of MS patients. The objective of this paper is to provide a survey of the pharmacology, pharmacokinetics, clinical trials, side effects and interactions of dalfampridine. It is used in treatment of MS patients. The clinical trials have been providing for the safety and efficacy of fampridine in MS patients with the degree of gait improvement as the main outcome.

Keywords: Dalfampridine, multiple sclerosis, gait, 4-AP.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More